• 瀏覽: 634
  • 回覆: 13
  • 追帖: 1
[隱藏]


巴西傳媒引述消息指,中國科興疫苗於巴西進行的第三期臨床研究的整體有效率(general efficacy)少於60%,較之前公佈的臨床有效率(clinical efficacy)為低。本港呼吸系統專科醫生梁子超表示,若整體有效率是指預防有病徵及沒有病徵的感染,有效率少於60%並不出奇,本港也有訂購的阿斯利康疫苗,預防沒有病徵的感染效率只有約58%,但仍然有待中國科興公佈全面的數據,才能確定該疫苗的效用

巴西傳媒引述消息指, 中國科興疫苗於巴西進行的第三期臨床研究的整體有效率(general efficacy)少於60%,較上周四公佈的臨床有效率(clinical efficacy)有78%為低。但之後進行臨床研究的巴西布坦坦研究所指報道純屬揣測,指該研究所會於香港時間今晚11時45分再舉行記者會交代研究結果

梁子超表示,暫時未知報道所指的整體有效率代表什麼,若整體有效率是包括預防有病徵及沒有病徵的感染,則少於60%並不出奇,現時其他疫苗沒有明確數據顯示接種後可預防沒有病徵的感染,即接種後仍有可能感染及成為隱形病人,而阿斯利康的研究顯示接種第一劑一半份量,及接種第二劑完整份量,在預防沒有病徵的感染約58%,而接種兩劑完整份量,在預防沒有病徵的感染只有約4%。

梁子超:未來6月疫苗接種難大覆蓋 仍要靠社交距離措施

梁子超表示,目前仍要待中國科興公佈全面第三期臨床研究數據,才能評論疫苗的效用及副作用。不過他指,相信現時面世的疫苗於個人保護效用是明確,最少能保護接種者自己,以及減少出現中度至嚴重病徵,減少對醫療系統的壓力,也可減少整體傳播。

他指,相信本港未來6個月疫苗接種不可能有大覆蓋,仍要靠社交距離措施減少社區傳播。
-----------------------------

================================================================================================================

唔使估估吓,好快巴西有關方面就會開記者會公佈詳細數據。

我份人好客觀,身體好誠實,輝瑞定科興,邊隻掂咪打邊隻囉,唔似得5毛藍屍,乜都唔理就話 「只揀科興」,連數據都未有呀!

新聞來源連結:
https://hk.appledaily.com/local/20210112/QTSWUVSE6JFXDLL6F7HSZ2S4XM/

[ 本帖最後由 hfceddie 於 2021-1-12 11:51 PM 編輯 ]



回覆 引用 TOP

fake  news


回覆 引用 TOP

明報話 : 
本港3款新冠疫苗第三期臨牀數據 保護率70至95% 科興疫苗100%防重症 許樹昌:未有長者及長期病患者數據


https://health.mingpao.com/新冠疫苗-本港3款新冠疫苗第三期臨牀數據-保護率70/



回覆 引用 TOP

有Ching 報導, 美國輝瑞疫苖的有效性只有19%-29%, 仲趴街喎


[隱藏]
Coronavirus: Scientists concerned by way data from Chinese drug firm Sinovac’s vaccine trials is coming out
Josephine Ma Published: 10:08pm, 12 Jan, 2021


Scientists have criticised the way data from the trials of a vaccine made by the Chinese drug company Sinovac has been released, saying it has caused confusion.

The complaints have prompted the pharmaceutical company's Brazilian partner, the Butantan Institute, to promise to provide the complete data at a conference on Tuesday, although it is not clear whether they will be able to address all the concerns raised.

Last week the institute released the long awaited efficacy data for the Sinovac vaccine after two delays in December. It said that the vaccine was found to be 78 per cent effective in a trial involving 12,400 health care workers in Sao Paulo state, describing it as a “fantastic” result.

But Sinovac and the Chinese government have yet to comment on the data.

Jerome Kim, director general of the International Vaccine Institute, criticised the way information was trickling out: “It is confusing when the group [Sinovac] that has access to the data from Indonesia, Turkey, and Brazil makes no official comment as its trial data are presented piecemeal. Are these authorised or unauthorised? If they are authorised, why doesn't the company comment?

“We don't know how the analysis was done. We also don't know if the analyses can be combined. Is this an official number that Sinovac will stand by?”

Scientists have also said that the information that has been made available about Sinovac's vaccine suggests that the efficacy level is much lower than 78 per cent.

Last week, Dimas Covas, director of the Butantan Institute, told a press conference that about 220 participants in the trials had been infected with Covid-19 – 160 in the placebo group and almost 60 of those who received the vaccine.

The trial protocol said that the number of volunteers receiving placebos and the vaccines should be evenly split, but the institute has not disclosed the actual numbers of the two groups.

“It was a 1:1 randomisation of 13,000 volunteers. So, 6,500 each to vaccine and placebo. Sixty infected vaccinated, 220 infected unvaccinated. Isn’t that less than 78 per cent? “ Kim said.

“It seems more like the AstraZeneca regimen [which achieved] 62 per cent, which is 70 per cent if they combined the half-dose group with the rest.”

Peter Smith, a professor of tropical epidemiology at the London School of Hygiene and Tropical Medicine, gave a similar assessment.

If the numbers of cases in vaccinated and placebo groups are truly 60 and 160 respectively, this corresponds to a vaccine efficacy of 62 per cent,” he said.

On Monday Reuters reported that the Butantan Institute would announce that the drug's “general efficacy” would be around 60 per cent, while the figure of 78 per cent referred to its “clinical efficacy”, although it is not clear how these figures were calculated.

There have also been partial disclosures of the results from two other Sinovac trials, in Indonesia and Turkey, with the former having 65 per cent efficacy and the latter 91 per cent, although these were based on a relatively small number of cases and infections.

"Looking at all of these partially reported results together would suggest a likely efficacy of the vaccine of around 65 to 70 per cent,” Smith said, which was “not dissimilar” to the results from the drug AstraZeneca produced in collaboration with Oxford University.

Smith said that piecemeal disclosures are not uncommon as it is a way to prevent insider trading, but the problem in this case is that very few details have been given in press releases and “to my knowledge, these results have not been presented either at international meetings or submitted to peer-reviewed journals. Without such further details there is bound to be speculation about the credibility of such data as has been released”.

The delays and lack of information also pose a problem for regulators waiting to approve the vaccines. For example, Hong Kong, which plans to buy 7.5 million doses of the vaccine, has had to delay the review of its emergency use application.

“There is no information on the side-effect profile, no information about the antibody level,” said a source close to the Hong Kong regulator, who declined to be named.

“We don't even know the age range [of trial participants] and any subjects with comorbid illnesses,” he said.

Professor Dale Godfrey, a senior principal research fellow and immunology theme leader at the University of Melbourne's Doherty Institute, said the vaccine looked promising but there were still questions that needed to be answered.

“It will be valuable to see more details about how vaccine recipients responded to the immunisations. What level of reactogenicity [a short-term reaction] was observed?

"Do these vaccines prevent infection and transmission, or just disease? Will this vaccine provide protection against the new mutant strains that are circulating? How durable will this immunity be? These questions will probably take longer to answer, but these are obviously important,” Godfrey said.

https://www.scmp.com/news/china/science/article/3117461/coronavirus-scientists-concerned-way-data-chinese-drug-firm

[ 本帖最後由 hfceddie 於 2021-1-13 12:11 AM 編輯 ]



回覆 引用 TOP

睇吓台灣電視台點講

https://youtu.be/PQ-ozP6qkl4



回覆 引用 TOP

顧L掂美國肺炎仲好啦, 死咗38萬美國人喇.


回覆 引用 TOP

整完出嚟都無無咩用


回覆 引用 TOP

China's Sinovac vaccine has 'general efficacy' of 50.4% in Brazil trials, says Butantan
JANUARY 13, 202112:44 AMUPDATED 12 MINUTES AGO

RIO DE JANEIRO (Reuters) - A coronavirus vaccine developed by China's Sinovac showed “general efficacy”of 50.38% in a late-stage trial in Brazil, the company's local partners said on Tuesday, revealing a more modest figure after pressure for more transparency.

On Thursday, Butantan officials had celebrated results showing 78% efficacy against mild COVID-19 cases, a rate they have since described as “clinical efficacy.”

Ricardo Palacios, medical director for clinical research at the Butantan biomedical center in Sao Paulo, said the new figure included infections that were so mild or asymptomatic that they did not need clinical care.

Reporting by Gabriel Stargardter and Pedro Fonseca; Editing by Brad Haynes
========================================================================================

50.4%有效率低係低啲。不過世衛標準話超過50%就O.K.。宜家仲突咗0.4%,掂!大家放心打!

[ 本帖最後由 hfceddie 於 2021-1-13 12:59 AM 編輯 ]



[隱藏]
有機可乘


回覆 引用 TOP

得啦, 毒媒, 唔好日日黑大陸又 成個狗頭咁用大陸野啦
快D 番去搵美爸



回覆 引用 TOP

引用:
原帖由 hfceddie 於 2021-1-13 12:54 AM 發表

China's Sinovac vaccine has 'general efficacy' of 50.4% in Brazil trials, says Butantan
JANUARY 13, 202112:44 AMUPDATED 12 MINUTES AGO

RIO DE JANEIRO (Reuters) - A coronavirus vaccine developed by ...
愛國者一定打科興,任何%都唔重要



回覆 引用 TOP

提示: 作者被禁止或刪除 內容自動屏蔽
引用:
原帖由 cwilson1 於 2021-1-13 12:02 AM 發表

有Ching 報導, 美國輝瑞疫苖的有效性只有19%-29%, 仲趴街喎
科興狗 blacklist你



有效機會高過贏買大細仲想點... 


方知卻原來,
不必盼蓬萊,
已是埋藏心內,
蓬萊就是愛.

回覆 引用 TOP

[按此隱藏 Google 建議的相符內容]